Table 1 Relationship between PNI and clinicopathological features in stage II GC

Gender (%)

Female

40 (30.08)

35 (35)

0.513

Male

93 (69.92)

65 (65)

Age (mean ± SD, years)

60.81 ± 11.94

56.69 ± 13.29

0.014

Age (%)

 < 60 years

56 (42.11)

55 (55.00)

0.069

 ≥ 60 years

77 (57.89)

45 (45.00)

Tumor location (%)

Lower

67 (50.38)

53 (53)

0.305

Middle

18 (13.53)

19 (19)

Upper

29 (21.80)

13 (13)

EGJ

19 (14.29)

15 (15)

Type of gastrectomy (%)

Partial

72 (54.14)

52 (52)

0.849

Total

61 (45.86)

48 (48)

Adjuvant chemotherapy (%)

No

44 (33.08)

31 (31)

0.845

Yes

89 (66.92)

69 (69)

CEA (ng/ml) (%)

 ≤ 5

112 (84.21)

87 (87)

0.682

 > 5

21 (15.79)

13 (13)

Vascular invasion (%)

Absence

105 (78.95)

78 (78)

0.99

Presence

28 (21.05)

22 (22)

Differentiation type (%)

Well differentiated

46 (34.59)

14 (14)

 < 0.001

Poorly differentiated

87 (65.41)

86 (86)

Lauren classification (%)

Intestinal

49 (36.84)

16 (16)

0.005

Diffuse

44 (33.08)

49 (49)

Mix

32 (24.06)

28 (28)

Others

8 (6.02)

7 (7)

Tumor diameter (cm) (mean ± SD)

4.02 ± 2.18

4.02 ± 2.13

0.999

Tumor diameter (cm) (%)

 ≤ 3

60 (45.11)

41 (41)

0.622

 > 3

73 (54.89)

59 (59)

T Stage (%)

T1

9 (6.77)

0 (0)

 < 0.001

T2

28 (21.05)

5 (5)

T3

95 (71.43)

86 (86)

T4a

1 (0.75)

9 (9)

Lymph node metastasis (%)

Absence

60 (45.11)

59 (59)

0.049

Presence

73 (54.89)

41 (41)

TNM Stage (%)

IIA

83 (62.41)

52 (52)

0.145

IIB

50 (37.59)

48 (48)

Overall survival (%)

Alive

107 (80.45)

69 (69)

0.063

Dead

26 (19.55)

31 (31)

Disease-free survival (%)

No recurrence

102 (76.69)

66 (66)

0.098

Recurrence or death

31 (23.31)

34 (34)